Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Haemonetics Corporation showed positive financial results, with a third quarter revenue of $336 million, an impressive 10% growth on both reported and organic bases.</li><li>Earnings per diluted share also grew by 22% compared with the previous year, which Haemonetics attributes to above-market growth and the successful achievement of important long range plan milestones.</li><li>The conference call presentation highlighted the revenue increases across segments, with the plasma revenue growing by 8% in the third quarter and the Hospital business revenue growth skyrocketing by an impressive 22%.</li></ul>

Haemonetics Corporation showed positive financial results, with a third quarter revenue of $336 million, an impressive 10% growth on both reported and organic bases.Earnings per diluted share also grew by 22% compared with the previous year, which Haemonetics attributes to above-market growth and the successful achievement of important long range plan milestones.The conference call presentation highlighted the revenue increases across segments, with the plasma revenue growing by 8% in the third quarter and the Hospital business revenue growth skyrocketing by an impressive 22%.

Haemonetics Corporation: Initiation Of Coverage - A Tale Of Strategic Acquisitions & Synergies! - Major Drivers

United States

Haemonetics Corporation designs, manufactures, and markets automated blood processing systems.  The Company's products are for use in surgical blood salvage, blood component collections, and plasma collections.  Haemonetics markets its products worldwide, primarily outside the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Haemonetics Corp (HAE US)

Haemonetics Corporation: Initiation Of Coverage - A Tale Of Strategic Acquisitions & Synergies! - Major Drivers

Haemonetics Corporation showed positive financial results, with a third quarter revenue of $336 million, an impressive 10% growth on both reported...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)